CYTH
Cyclo Therapeutics Inc · NASDAQ
- Sector Health Technology
- Industry Biotechnology
- Website cyclotherapeutics.com
- Employees(FY) 9
- ISIN US23254X2018
Performance
-3.45%
1W
+14.75%
1M
-20.45%
3M
+2.94%
6M
-11.95%
YTD
+26.13%
1Y
Profile
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of neurodegenerative diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo that is in Phase IIb clinical trials for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Technical Analysis of CYTH 2024-05-10
Overview:
In analyzing the technical indicators for CYTH over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days.
Trend Analysis:
- Moving Averages (MA): The 5-day Moving Average (MA) has been fluctuating around the c...
Recent News & Updates
- 2024-05-15 20:05
- 2024-05-15 19:53
- 2024-03-18 18:53
- 2024-03-17 21:05
- 2024-03-13 21:34
- 2024-03-13 05:04
- 2024-01-28 20:15
- 2023-12-27 03:15
- 2023-12-17 20:15
- 2023-12-14 03:01
- 2023-11-20 19:05
- 2023-11-14 19:05
- 2023-10-30 04:01
- 2023-10-22 20:05
- 2023-10-04 20:05
- 2023-09-20 21:35
- 2023-09-20 20:05
- 2023-08-14 20:05
- 2023-08-01 20:16
- 2023-06-29 01:32
- 2023-06-13 04:01
- 2023-06-11 20:05
- 2023-06-04 20:05
- 2023-05-14 20:05
- 2023-05-01 20:12
- 2023-04-20 20:05
- 2023-03-19 20:05
- 2023-01-11 00:00
- 2023-01-10 19:05
- 2023-01-09 19:05
Page 1 of 4
previousnext